基蛋生物收盘下跌1.25%，滚动市盈率21.77倍，总市值43.97亿元

Core Viewpoint - The company,基蛋生物, is currently facing a decline in stock price and performance metrics, with a significant gap between its price-to-earnings ratio and the industry average, indicating potential undervaluation in the context of its sector [1][2]. Company Summary - 基蛋生物's closing stock price is 8.67 yuan, down 1.25%, with a rolling PE ratio of 21.77 times and a total market capitalization of 4.397 billion yuan [1]. - The company specializes in the research, production, sales, and service of in vitro diagnostic reagents and instruments, particularly in the POCT (Point of Care Testing) field, and is recognized as a key high-tech enterprise under the National Torch Program [1]. - The latest quarterly report for Q1 2025 shows a revenue of 244 million yuan, a year-on-year decrease of 24.08%, and a net profit of 64.31 million yuan, down 25.24%, with a gross margin of 77.15% [1]. Industry Summary - The average PE ratio for the medical device industry is 55.76 times, with a median of 39.14 times, positioning 基蛋生物 at the 46th rank within the industry [1][2]. - The industry shows a wide range of PE ratios, with the highest being 20.62 times for 安图生物 and the lowest at 11.18 times for 九安医疗, indicating varying levels of market valuation across different companies [2].